Posters

36-month results of an ab interno canaloplasty (ABiC) case series

Poster Details

First Author: N.Körber GERMANY

Co Author(s):                        

Abstract Details

Purpose:

The aim of this case series study was to describe and evaluate the ability of ABiC to lower IOP and reduce dependence on medication in patients with primary open-angle glaucoma (POAG).

Setting:

Augencentrum, Köln, Germany

Methods:

This was a single center consecutive case series study to evaluate the efficacy of ABiC in reducing IOP and dependence on glaucoma medication out to 36 months postoperative. Secondary endpoints included surgical and postsurgical complications. All patients underwent ABiC under local anesthesia. The iTrack™ 250-micron microcatheter (Ellex Medical Lasers Pty Ltd, Adelaide, Australia) with a fiber optic light and lumen was passed through a clear corneal incision (1.8 mm in pseudophakic eyes and 2.4 mm in combined cases) and then through a small opening in the trabecular meshwork in order to circumferentially viscodilate and intubate Schlemm’s canal,

Results:

Preoperatively, the mean IOP was 19,9 mm Hg (St dev 5,31, n=26) with an average number of medications of 1,9. One month after ABiC, the IOP was 14,4 mm Hg +- 3,51, n=25). At 6 months, it was 14,5 mm Hg +- 2,28, n=20). At 12 months, it remained stable at 14,8 mm Hg (+-2,78, n=21). At 2 years after ABiC, the mean IOP was 15,6 mmHg (+- 3,42, n=24) and at 3 years, 14,8 mm Hg (+- 3,68, n=14). The mean number of medications at the last vist was reduced to 0.88.

Conclusions:

Although the sample size is a limiting factor, the findings indicate that ABiC lowers IOP and medication dependency comparable to conventional canaloplasty, and maintains this reduction out past three years. The procedure was also straightforward to perform in this group of patients, with minimal complications. Nevertheless, long-term follow-up in a large patient cohort is required to confirm the efficacy of this minimally-invasive glaucoma procedure.

Financial Disclosure:

None